153 related articles for article (PubMed ID: 30170409)
41. The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
Chen YY; Huang YJ; Huang HK; Chang H; Lee SC; Shieh YS; Huang TW
J Cancer Res Clin Oncol; 2020 May; 146(5):1299-1306. PubMed ID: 32107626
[TBL] [Abstract][Full Text] [Related]
42. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
[TBL] [Abstract][Full Text] [Related]
43. USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma.
Hu J; Yang D; Zhang H; Liu W; Zhao Y; Lu H; Meng Q; Pang H; Chen X; Liu Y; Cai L
Lung Cancer; 2015 Jun; 88(3):239-45. PubMed ID: 25907317
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer.
Raungrut P; Wongkotsila A; Lirdprapamongkol K; Svasti J; Geater SL; Phukaoloun M; Suwiwat S; Thongsuksai P
Asian Pac J Cancer Prev; 2014; 15(8):3513-8. PubMed ID: 24870749
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
47. The prognostic significance of N-myc downregulated gene 1 in lung adenocarcinoma.
Dai T; Dai Y; Murata Y; Husni RE; Nakano N; Sakashita S; Noguchi M
Pathol Int; 2018 Apr; 68(4):224-231. PubMed ID: 29431240
[TBL] [Abstract][Full Text] [Related]
48. Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.
Matsumoto T; Nagashio R; Ryuge S; Igawa S; Kobayashi M; Fukuda E; Goshima N; Ichinoe M; Jiang SX; Satoh Y; Masuda N; Murakumo Y; Saegusa M; Sato Y
Pathol Int; 2018 Apr; 68(4):232-240. PubMed ID: 29431238
[TBL] [Abstract][Full Text] [Related]
49. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.
Itakura M; Terashima Y; Shingyoji M; Yokoi S; Ohira M; Kageyama H; Matui Y; Yoshida Y; Ashinuma H; Moriya Y; Tamura H; Harigaya K; Matushima K; Iizasa T; Nakagawara A; Kimura H
Br J Cancer; 2013 Sep; 109(5):1100-8. PubMed ID: 23922113
[TBL] [Abstract][Full Text] [Related]
50. Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma.
Chang YH; Chen CM; Chen HY; Yang PC
Sci Rep; 2015 Jun; 5():10979. PubMed ID: 26042604
[TBL] [Abstract][Full Text] [Related]
51. [Correlations between OCT4 expression and clinicopathological factors and prognosis of patients with lung adenocarcinoma].
Zhang X; Wang H; Jin B; Dong Q; Huang J; Han B
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):197-202. PubMed ID: 23601300
[TBL] [Abstract][Full Text] [Related]
52. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
[TBL] [Abstract][Full Text] [Related]
53. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.
Akagi I; Okayama H; Schetter AJ; Robles AI; Kohno T; Bowman ED; Kazandjian D; Welsh JA; Oue N; Saito M; Miyashita M; Uchida E; Takizawa T; Takenoshita S; Skaug V; Mollerup S; Haugen A; Yokota J; Harris CC
Cancer Res; 2013 Jul; 73(13):3821-32. PubMed ID: 23639940
[TBL] [Abstract][Full Text] [Related]
54. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
55. Epidermal growth factor receptor-GEP100-Arf6 axis affects the prognosis of lung adenocarcinoma.
Oka S; Uramoto H; Shimokawa H; Yamada S; Tanaka F
Oncology; 2014; 86(5-6):263-70. PubMed ID: 24902879
[TBL] [Abstract][Full Text] [Related]
56. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
Hsu LH; Liu KJ; Tsai MF; Wu CR; Feng AC; Chu NM; Kao SH
Cancer Sci; 2015 Jan; 106(1):51-9. PubMed ID: 25338663
[TBL] [Abstract][Full Text] [Related]
57. High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma.
Ding X; Zhang J; Shi M; Liu D; Zhang L; Zhang R; Su B; Ai K
Clin Transl Oncol; 2021 Jan; 23(1):35-42. PubMed ID: 32472456
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
60. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
